Qube Research & Technologies Ltd - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 78 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Qube Research & Technologies Ltd ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$16,818
-81.8%
21,561
-78.5%
0.00%
Q2 2023$92,639
+77.7%
100,150
+109.4%
0.00%
Q1 2023$52,128
+32.2%
47,824
+77.1%
0.00%
Q4 2022$39,421
-47.4%
27,001
-38.6%
0.00%
-100.0%
Q2 2022$75,000
+127.3%
43,966
+261.4%
0.00%0.0%
Q1 2020$33,00012,1670.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q3 2023
NameSharesValueWeighting ↓
MPM ASSET MANAGEMENT LLC 6,287,101$4,903,9392.63%
Syncona Portfolio Ltd 1,377,294$1,074,2891.60%
MPM BioImpact LLC 5,095,912$3,974,8111.06%
NEA Management Company, LLC 17,079,778$13,322,2271.03%
TANG CAPITAL MANAGEMENT LLC 5,166,954$4,030,2240.57%
PFM Health Sciences, LP 10,423,135$8,130,0450.38%
Matrix Capital Management Company, LP 38,974,185$30,399,8640.36%
Long Focus Capital Management, LLC 10,963,158$8,551,2630.31%
Acuitas Investments, LLC 479,764$374,2160.22%
Endurant Capital Management LP 311,944$243,3160.22%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders